🔍

ASTRAZEN - Astrazeneca Phar

📊 NSE: ASTRAZEN 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/13/2025 18:40

📢 Recent Corporate Announcements

AstraZeneca India Receives CDSCO Approval for Calquence (Acalabrutinib) Additional Indication

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 10 Apr 2026, 05:48 PM

AstraZeneca Pharma India has received regulatory approval from the CDSCO to import and market Acalabrutinib 100 mg tablets (Calquence) for an additional indication. The drug is now authorized for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) when used in combination with venetoclax. This approval expands the company's oncology portfolio in India, targeting a broader patient base. The commercial launch for this indication remains subject to any further statutory approvals.

Received CDSCO permission on April 9, 2026, for Acalabrutinib 100 mg tablets (Calquence).
New indication covers previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Approval includes combination therapy with venetoclax, with or without obinutuzumab.
Expands AstraZeneca's therapeutic footprint in the high-growth oncology segment in India.

💡 Investors should monitor the commercial uptake of Calquence for this new indication as it strengthens the company's specialized medicine portfolio. This regulatory milestone is a positive driver for long-term revenue growth in the oncology division.

AstraZeneca Pharma India Proposes Shifting Registered Office to Maharashtra

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 10 Apr 2026, 05:25 PM

AstraZeneca Pharma India Limited has initiated a postal ballot process to seek shareholder approval for shifting its registered office from Karnataka to Maharashtra. The e-voting period is scheduled to run from April 12, 2026, to May 11, 2026, with a cut-off date of April 3, 2026. This relocation requires a Special Resolution and subsequent approval from the Regional Director/Central Government. The move involves a formal amendment to the company's Memorandum of Association.

Proposal to relocate the registered office from the State of Karnataka to the State of Maharashtra.
E-voting period spans 30 days, commencing April 12, 2026, and ending May 11, 2026.
Cut-off date for determining shareholder eligibility for voting is April 3, 2026.
The change is subject to the approval of the Central Government through the Regional Director.

💡 This is a routine administrative and regulatory matter with no direct impact on the company's business fundamentals; shareholders may cast their votes through the NSDL e-voting platform.

AstraZeneca India Appoints New Medical Director (Oncology) and Market Access Director

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 31 Mar 2026, 07:48 PM

AstraZeneca Pharma India has announced two key leadership appointments effective April 1, 2026, to strengthen its Oncology and Market Access divisions. Dr. Shashank Srinivasan, a clinical oncologist and former Pfizer lead, has been appointed as Medical Director for the Oncology Business Unit. Additionally, Mr. Venkat Natarajan, who has approximately 20 years of industry experience, has been promoted to Director of the Market Access Business Unit. These strategic appointments are aimed at enhancing the company's precision care delivery and patient affordability programs in India.

Dr. Shashank Srinivasan appointed as Medical Director – Oncology Business Unit effective April 1, 2026.
Mr. Venkat Natarajan promoted to Director – Market Access Business Unit effective April 1, 2026.
Mr. Natarajan brings nearly 20 years of experience from major firms including Pfizer, Novartis, and MSD.
Dr. Srinivasan is an alumnus of Tata Memorial Hospital with specialized expertise in GI and Lung cancers.
The appointments focus on strengthening the company's oncology portfolio and state-level insurance access models.

💡 These leadership changes reinforce AstraZeneca's focus on the high-growth oncology segment and market penetration. Investors should watch for improved execution in product launches and expanded market access under the new leadership.

AstraZeneca Pharma India Shareholders Approve Material Related Party Transactions

🟡 NEUTRAL ⭐ 5/10

REGULATORY 📅 31 Mar 2026, 04:02 PM

AstraZeneca Pharma India Limited has announced that its shareholders have approved ordinary resolutions regarding material transactions with related parties via a postal ballot. The voting results, declared on March 31, 2026, confirm that the resolutions were passed by non-related members with the requisite majority. This approval is a mandatory regulatory requirement under SEBI (LODR) Regulations for significant business dealings with group entities. The successful vote ensures the company remains compliant while executing its operational strategy involving parent or sister concerns.

Ordinary resolutions for Material Related Party Transactions passed with requisite majority.
Voting results finalized on March 31, 2026, following a Postal Ballot notice dated February 11, 2026.
Approval obtained specifically from non-related members to ensure fair corporate governance.
Compliance maintained under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 No immediate action is required as this is a routine regulatory approval for business operations. Investors should monitor future financial statements to understand the scale and impact of these related party transactions on margins.

AstraZeneca Pharma India Announces Resignation of Non-Executive Director Jesús Diaz-Ropero Esteso

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 20 Mar 2026, 12:10 PM

AstraZeneca Pharma India Limited has informed the exchanges regarding the resignation of Mr. Jesús Diaz-Ropero Esteso from his position as a Non-Executive Director. The resignation was effective from March 19, 2026, and includes his withdrawal from all associated Board Committees. The company stated the reason for his departure is a transition from his current responsibilities. This move is part of routine board changes and is not expected to impact the company's core operations.

Mr. Jesús Diaz-Ropero Esteso resigned as Non-Executive Director effective March 19, 2026.
The resignation includes cessation of membership in all Board Committees served by the director.
The departure is attributed to a transition from current responsibilities within the organization.
The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should treat this as a routine management update; no immediate action is required as it does not affect the company's financial or operational outlook.

AstraZeneca India Receives CDSCO Approval for Imfinzi to Treat Liver Cancer (uHCC)

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 17 Mar 2026, 03:07 PM

AstraZeneca Pharma India has received approval from the CDSCO to import and market Durvalumab (Imfinzi) for an additional indication in India. The drug is now indicated for treating unresectable hepatocellular carcinoma (uHCC) in patients who have not received prior systemic therapy. This approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL. This expansion into liver cancer treatment strengthens the company's oncology portfolio and opens a new revenue stream in the Indian market.

Received CDSCO permission for import and distribution of Durvalumab (Imfinzi) for a new indication
Indicated for unresectable hepatocellular carcinoma (uHCC) in treatment-naive patients
Approval covers two formulations: 120 mg/2.4 mL and 500 mg/10 mL solution for infusion
Expands AstraZeneca's oncology portfolio and addressable market in India

💡 Investors should view this as a positive development for long-term growth in the oncology segment. Monitor the commercial rollout and its impact on the company's specialty care revenue in upcoming quarters.

AstraZeneca Pharma India to Close Trading Window from March 16, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Mar 2026, 05:01 PM

AstraZeneca Pharma India Limited has announced the closure of its trading window for equity shares starting March 16, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's upcoming financial disclosures. The window will remain closed until 48 hours after the declaration of the audited financial results for the quarter and year ending March 31, 2026. This is a standard regulatory procedure to prevent insider trading during the period when price-sensitive information is being finalized.

Trading window for dealing in Equity Shares will be closed from March 16, 2026.
Closure is related to the upcoming audited financial results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the official declaration of the financial results.
The announcement is made pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory filing with no impact on company fundamentals. Investors should monitor the upcoming earnings release for actual performance data.

AstraZeneca Pharma India Appoints Sandhya Tejaswini Amanna as Director - Legal

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 11 Mar 2026, 04:39 PM

AstraZeneca Pharma India Limited has appointed Mrs. Sandhya Tejaswini Amanna as Director - Legal, effective March 18, 2026. Mrs. Amanna is a seasoned professional with over 20 years of experience in the legal, compliance, and governance sectors across pharmaceutical and FMCG industries. She joins the company from Danone India, where she served as the Head of Legal, Compliance, and Secretarial. Her extensive background in intellectual property litigation and legal risk management is expected to strengthen the company's internal governance frameworks.

Appointment of Mrs. Sandhya Tejaswini Amanna as Director - Legal effective from March 18, 2026.
The appointee brings over 20 years of professional experience in manufacturing, FMCG, and pharmaceutical sectors.
Previously served as Head of Legal, Compliance, and Secretarial at Danone India.
Expertise includes end-to-end contract management, IP litigation, and legal risk management.
The appointment was approved by the Board based on the recommendation of the Nomination and Remuneration Committee.

💡 This is a routine senior management appointment and does not require any immediate portfolio action. Investors should view this as a move to strengthen the company's legal and compliance leadership.

AstraZeneca Pharma India Seeks Approval for ₹3,900 Cr Related Party Transactions

🟡 NEUTRAL ⭐ 7/10

REGULATORY 📅 27 Feb 2026, 04:56 PM

AstraZeneca Pharma India Limited has issued a postal ballot notice to seek shareholder approval for material related party transactions (RPT) for the 2026-27 fiscal year. The company proposes transactions worth up to ₹2,400 crore with AstraZeneca UK Limited and up to ₹1,500 crore with AstraZeneca AB, Sweden. These transactions cover the purchase, transfer, or receipt of products, goods, and services essential for operations. The e-voting period is scheduled from February 28 to March 29, 2026, with results expected by March 31, 2026.

Proposed transactions with AstraZeneca UK Limited capped at ₹2,400 crore for FY 2026-27.
Proposed transactions with AstraZeneca AB, Sweden capped at ₹1,500 crore for FY 2026-27.
Total value of material related party transactions under consideration is ₹3,900 crore.
E-voting period runs from February 28, 2026, to March 29, 2026.
Transactions include purchase of products, goods, materials, and reimbursement of transfer price or other obligations.

💡 Investors should monitor the voting results and review the explanatory statement to ensure these large-scale transactions with parent entities are conducted at arm's length.

AstraZeneca Pharma India Submits SEBI Regulation 74(5) Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 19 Feb 2026, 06:03 PM

AstraZeneca Pharma India Limited has filed a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by the company's Registrar and Transfer Agent, Integrated Registry Management Services, confirms the processing of dematerialization requests. It verifies that physical share certificates were cancelled and the depository's name was updated in the company's records. This filing is a mandatory administrative procedure for listed companies in India to maintain accurate electronic shareholding data.

Submission of compliance certificate for SEBI (Depositories and Participants) Regulations, 2018.
Confirmation provided by Registrar and Transfer Agent, Integrated Registry Management Services Private Limited.
Certificate dated February 5, 2026, ensures the integrity of the dematerialization process.

💡 This is a routine administrative update with no impact on company fundamentals; no action is necessary for shareholders.

AstraZeneca Pharma India Assigned ESG Rating of 70 by NSE Sustainability

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 18 Feb 2026, 03:33 PM

AstraZeneca Pharma India Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 70 by NSE Sustainability Ratings & Analytics Limited. This rating is based on publicly available information pertaining to the financial year 2024-25. The company clarified that it did not formally engage the agency, and the report was prepared independently. This disclosure is in compliance with the latest SEBI mandates regarding ESG reporting for listed entities.

NSE Sustainability assigned an ESG rating of 70 to AstraZeneca Pharma India.
The rating is based on publicly available data for the FY 2024-25 period.
The assessment was conducted independently by the agency without company solicitation.
The disclosure follows SEBI Master Circular requirements dated January 30, 2026.

💡 Investors should view this ESG score as a benchmark for the company's sustainability performance relative to peers. No immediate trading action is required as this is a routine regulatory disclosure.

AstraZeneca India Q3 Revenue Surges 39% to INR 6,115.7 Mn; 8 New Regulatory Approvals Secured

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 07:05 PM

AstraZeneca Pharma India reported a robust 39% YoY growth in total revenue for Q3 FY 2025-26, reaching INR 6,115.7 Mn. The growth was primarily driven by the Oncology segment, which contributed INR 4,395.9 Mn, and Biopharmaceuticals at INR 1,377.4 Mn. The company demonstrated strong pipeline execution with 8 new regulatory approvals over the past nine months, including key indications for Durvalumab and Osimertinib. Profit after tax for the quarter stood at INR 465.4 Mn, supported by consistent performance across all therapy areas.

Total revenue for Q3 FY 2025-26 grew 39% YoY to INR 6,115.7 Mn.
Oncology segment contributed INR 4,395.9 Mn, representing approximately 72% of total quarterly revenue.
Secured 8 new regulatory approvals in 9 months, including treatments for endometrial cancer, MIBC, and rare diseases.
9-month (Apr-Dec '25) total revenue reached INR 16,969.7 Mn with a Profit Before Tax of INR 1,982.3 Mn.
Launched Eculizumab, the first anti-complement therapy in India for rare diseases aHUS and PNH.

💡 Investors should note the strong revenue momentum and the significant expansion of the product portfolio through 8 new approvals. The company's focus on high-value oncology and rare disease segments suggests a positive outlook for long-term margin improvement.

AstraZeneca Pharma India Appoints Tanya Sanish as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 11 Feb 2026, 05:50 PM

AstraZeneca Pharma India Limited has appointed Ms. Tanya Sanish as the Company Secretary and Compliance Officer, effective February 23, 2026. Ms. Sanish is a seasoned professional with over 15 years of experience in corporate governance, capital markets, and M&A transactions. She joins from Piramal Pharma Limited, where she held a similar leadership role, and has previously worked with Pidilite Industries. This appointment is part of the company's effort to maintain robust regulatory compliance and governance standards.

Appointment of Ms. Tanya Sanish as Company Secretary and Compliance Officer effective February 23, 2026.
The appointee brings over 15 years of experience in corporate governance and Indian securities laws.
Previously served as Company Secretary at Piramal Pharma Limited and held positions at Pidilite Industries.
Expertise includes managing high-value fund-raising exercises such as rights issues, QIPs, and debt issuances.

💡 This is a routine management update and does not require any immediate investment action. Investors should view the appointment of an experienced professional as a positive step for long-term governance.

AstraZeneca India Gets CDSCO Approval for Imfinzi in Endometrial Cancer Treatment

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 10 Feb 2026, 10:56 AM

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab (Imfinzi) for an additional indication. The drug is now approved for first-line treatment of adults with primary advanced or recurrent endometrial cancer in combination with chemotherapy. This approval covers two dosage forms: 120 mg/2.4 mL and 500 mg/10 mL. This regulatory milestone allows the company to expand its oncology portfolio and address a critical therapeutic area in the Indian market.

Received CDSCO permission to import and distribute Durvalumab (Brand: Imfinzi) for a new indication.
Approved for first-line treatment of primary advanced or recurrent endometrial cancer in combination with chemotherapy.
Available in two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL solution for infusion.
Includes maintenance treatment as monotherapy for mismatch repair deficient (dMMR) endometrial cancer.

💡 This is a positive development that strengthens AstraZeneca's oncology pipeline in India. Investors should monitor the impact on specialty segment revenues in future earnings reports as the product is commercialized for this new indication.

AstraZeneca Pharma India Receives ESG Score of 64.4 (Grade B) from SES ESG Research

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 02 Feb 2026, 06:14 PM

AstraZeneca Pharma India Limited has disclosed its ESG rating as assigned by SES ESG Research Private Limited for FY 2024-25. The company received an adjusted ESG score of 64.4, which corresponds to a Grade B rating. This assessment was conducted independently by SES using publicly available information and was not a paid engagement by the company. The disclosure is in compliance with SEBI's updated regulations regarding ESG transparency for listed entities.

SES ESG Research assigned an adjusted ESG score of 64.4 to the company.
The company achieved a Grade B rating based on data from the 2024-25 financial year.
The rating was unsolicited and based entirely on publicly available information.
Compliance filing follows SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

💡 Investors should note this as a baseline for the company's sustainability performance; while Grade B is stable, focus remains on core pharmaceutical growth and pipeline developments.

View All ASTRAZEN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 29% YoY to INR 1,300 Cr. Product sales crossed INR 1,000 Cr for the first time. Q1 FY25 revenue grew 45% YoY excluding Lynparza, and 8% on a quarter-on-quarter basis.

Geographic Revenue Split

Primarily focused on the Indian pharmaceutical market, which is valued at INR 2,16,091 Cr (USD 26.04 billion). Specific % split between domestic and overseas markets not disclosed.

Profitability Margins

Gross margins have declined in the last two quarters of FY24 and Q1 FY25. This is attributed to a shift toward becoming a specialist organization focusing on trading products (imported from parent entities) rather than local manufacturing.

EBITDA Margin

Core profitability metrics not explicitly disclosed, but EPS grew 63% YoY to INR 64.60.

Capital Expenditure

Not disclosed in available documents, though the company is exiting its Bangalore manufacturing site, resulting in a Q1 FY25 write-off of INR 57 Cr.

⚙️ Operational Drivers

Raw Materials

Traded goods and raw materials for pharmaceutical formulations in Oncology, Cardiovascular, Diabetes, and Respiratory therapies.

Import Sources

United Kingdom and Sweden.

Key Suppliers

AstraZeneca UK Limited (INR 831.08 Cr in purchases) and AstraZeneca AB, Sweden (INR 295.28 Cr in purchases).

Capacity Expansion

The company is currently exiting its Bangalore manufacturing site as part of a strategic review of its Global Manufacturing and Supply Network and is exploring a buyer for the site.

Raw Material Costs

Total related party purchases of raw materials and traded goods amounted to approximately INR 1,126.36 Cr in FY25. Procurement is conducted at arm's length.

Manufacturing Efficiency

Maintained zero Lost Time Injuries (LTI) and seamless supply to patients despite the planned exit from the Bangalore facility.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Strategy focused on 'Growth through Innovation' by bringing innovative medicines faster to India and improving patient access. This includes 9 regulatory approvals in FY24 and a strategic alliance with Sun Pharma to leverage their chronic therapy coverage.

Products & Services

Medicines for Oncology, Cardiovascular, Renal, Metabolism (CVRM), Diabetes, Respiratory, and Rare Diseases.

Brand Portfolio

Tagrisso, Imfinzi, Brilinta, Lynparza, Forxiga, Crestor, Enhertu, Seloken XL, Zoladex 10.8, Betaloc, Fasenra, Xigduo, Symbicort.

New Products/Services

9 regulatory approvals achieved in FY24; ongoing focus on the global pipeline to reach parent company's USD 80 billion target by 2030.

Market Expansion

Expanding reach in India through a strategic alliance with Sun Pharmaceutical Industries Limited to leverage their strong presence in chronic therapies.

Market Share & Ranking

Among the top 10 fastest-growing pharma companies in India; improved 3 ranks in FY24.

Strategic Alliances

Sun Pharmaceutical Industries Limited (distribution/reach), Mankind Pharma (recognition of deferred revenue/amortization).

🌍 External Factors

Industry Trends

Indian pharma market grew 7.6% to INR 2,16,091 Cr. MNCs grew 6.05% while Indian companies grew 7.9%. The market is largely out-of-pocket and fragmented.

Competitive Landscape

Highly competitive and fragmented; Indian companies hold an 83% market share by value.

Competitive Moat

Moat is built on a strong innovation pipeline from the parent company and a leading position in high-growth segments like Oncology (Tagrisso sales of INR 319.9 Cr).